Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-01-24

Clinical Trial Update: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study [Phase 3]

View source ↗

Summary

The Phase 3 EINSTEIN DVT trial evaluated rivaroxaban for the treatment of acute symptomatic deep vein thrombosis; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thrombosis | Phase 3 | Status: COMPLETED | Results posted: 2013-01-24